{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-004265","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.166381+00:00","generated_at":"2026-05-23T14:57:09.804048+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dermata's XYNGARI Phase 3 trial shows stat sig benefit at 4 weeks in moderate-to-severe acne","bullets":["IGA treatment success: 11.9% XYNGARI vs 6.2% placebo (p<0.05) at week 4, after 4 weekly doses.","Inflammatory lesion count mean change: -11.4 XYNGARI vs -8.6 placebo (p<0.001).","Non-inflammatory lesion count mean change: -12.4 XYNGARI vs -8.8 placebo (p<0.001).","Data support earlier positive week 12 topline results for all primary endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-004265","json":"https://secwatch.observer/filing/0001654954-25-004265.json","markdown":"https://secwatch.observer/filing/0001654954-25-004265.md","text":"https://secwatch.observer/filing/0001654954-25-004265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/0001654954-25-004265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:57:09.804048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}